Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration.

Usha Chakravarthy,Clare Bailey,David Brown,Peter Campochiaro, Mark Chittum,Karl Csaky,Adnan Tufail,Paul Yates,Patrick Cech,Mylene Giraudon,Paul Delmar,Piotr Szczesny,Jayashree Sahni,Anne Boulay,Sandra Nagel,Sabine Fürst-Recktenwald,Dietmar Schwab

Ophthalmology Retina（2017）

引用 63|浏览29

暂无评分

摘要

RG7716 was well tolerated and exhibited an overall favorable safety profile, with evidence of improvements in BCVA and anatomic parameters. These data support further evaluation of RG7716 in phase II trials.

查看译文

关键词

AE,AMD,BCVA,CNV,CST,FcRn,IgG,IOP,MD,PI,SD,SoC,TEAE,Tie2,VEGF

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要